Clinical Trial Update: A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

View source ↗

Summary

A terminated clinical trial evaluated a 12-gene blood-based signature for detecting metastatic bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer | Status: TERMINATED